- Home
- CUE vs SACH Comparison
CUE vs SACH Comparison
Compare CUE & SACH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CUE | SACH |
|---|---|---|
| Founded | 2014 | 2010 |
| Country | United States | United States |
| Employees | N/A | 29 |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.1M | 48.6M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | CUE | SACH |
|---|---|---|
| Price | $0.31 | $1.10 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 3 |
| Target Price | ★ $3.00 | $2.00 |
| AVG Volume (30 Days) | ★ 316.8K | 128.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 18.52% |
| EPS Growth | ★ 35.14 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,287,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $25.00 | $1.17 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 69.16 | N/A |
| 52 Week Low | $0.23 | $0.80 |
| 52 Week High | $1.12 | $1.35 |
Technical Indicators
Market Signals| Indicator | CUE | SACH |
|---|---|---|
| Relative Strength Index (RSI) | 50.62 | 67.96 |
| Support Level | $0.26 | $1.04 |
| Resistance Level | $0.36 | $1.13 |
| Average True Range (ATR) | 0.02 | 0.03 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 60.89 | 76.27 |
Price Performance
Historical ComparisonAbout CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About SACH Sachem Capital Corp.
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.